Testicular tumors Flashcards
What are the MC types of testicular tumors
Germ cell (seminoma) (non-seminoma: mixed, embryonal, yolk sac, choriocarcinoma, teratoma) Stromal (leydig, sertoli, granulosa cell)
RF for testicular tumors include
Cryptorchidism (undescended testis)
FHx
personal Hx
HIV
What were previously but NO longer considered RF for testicular cancer
Diethylstilbestrol exposure in utero
testicular atrophy
trauma
What are Sx of testicular tumors
Painless mass or swelling in testicle
R>L
Back pain or abdominal mass
What are the ways testicular tumors can metastasize
Bilateral testis
Lymph to retroperitoneal nodes
Distant to lung, liver, brain, bone, kidney, adrenal, GI, spleen
What labs are useful in evaluating testicular tumors
H&P US Tumor markers (AFP, beta HCG, LDH) LFT, CBC, Creatinine CXR
How do you treat lymphoma
Refer to oncology
How do you treat testicular tumors
Radical inguinal orchiectomy- outpt, scrotal compression, ice pack, elevate, po analgesics
can do sperm banking and prosthesis
How long after orchiectomy should you wait before retesting testing tumor markers
Five half lives! AFP: 5 weeks B-HCG: 1-2 weeks LDH: 3 weeks Also recheck CT chest/abd/pelvis s/p orchiectomy
How do you stage testicular tumors
Tumor, Nodes, Mets (TNM) T: 4 stages N: 3 stages D: stages M0-M1b S: serum tumor markers post orchiectomy
Post orchiectomy, depending on compliance, what can your work up include
Surveillance
Chemo (carboplatin. bleomycin. etoposide. cisplatin)
Radiation
Retroperitoneal Lymph Node Dissection
What does Tumor marker surveillance include post-orchiectomy
q3-4 mo. x 2 years
q 6-12 mo. x 2 years
annually for life
(also do H&P at these times)
What does imaging surveillance post orchiectomy include
CT A/P q6 mo x 2 years
CT A/P q6-12 mo q 1 year
annually x 2 years
-CXR as indicated
What are ADE of chemotherapy s/p orchiectomy
Myelosuppression, nausea, fatigue
+/- infertility
What are ADE of radiation s/p orchiectomy
Acute: nausea (also vomiting, fatigue, myelosuppression)
Later: PUD, gastritis, high risk CV death and secondary cancer